Clinical Trial Update: A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating subcutaneous durvalumab for non-small cell lung cancer and small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 1 | Status: TERMINATED